Neurocrine Biosciences (NBIX) Share-based Compensation Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Share-based Compensation Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 5.26% |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | -36.59% |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | -0.11% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | -49.74% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -18.06% |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 23.11% |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | -65.00% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 24.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.11% |
| Mar 31, 2026 | 5.49% |
| Sep 30, 2025 | -187.93% |
| Jun 30, 2025 | 248.73% |
| Mar 31, 2025 | 18.65% |
| Dec 31, 2024 | 48.88% |
| Sep 30, 2024 | 151.26% |
| Jun 30, 2024 | -151.82% |
| Mar 31, 2024 | 11.53% |
| Dec 31, 2023 | 134.41% |
| Sep 30, 2023 | -63.12% |
| Jun 30, 2023 | 285.14% |
| Mar 31, 2023 | 7.84% |
| Dec 31, 2022 | -464.04% |
| Sep 30, 2022 | 249.33% |
| Jun 30, 2022 | -181.32% |
| Mar 31, 2022 | 131.25% |
| Dec 31, 2021 | 69.52% |
| Sep 30, 2021 | -53.04% |
| Jun 30, 2021 | 299.56% |